Alnylam Pharmaceuticals
ALNY
#564
Rank
โ‚น4.019 T
Marketcap
โ‚น30,304
Share price
0.51%
Change (1 day)
46.36%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -โ‚น21.44 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น3.21 Billion. In 2024 the company made an earning of -โ‚น21.44 Billion, an increase over its 2023 earnings that were of -โ‚น28.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-โ‚น21.44 Billion-24.59%
2023-โ‚น28.43 Billion-67.84%
2022-โ‚น88.39 Billion36.93%
2021-โ‚น64.55 Billion-8.04%
2020-โ‚น70.2 Billion-15.66%
2019-โ‚น83.23 Billion12.23%
2018-โ‚น74.16 Billion62.91%
2017-โ‚น45.53 Billion17.78%
2016-โ‚น38.65 Billion43.44%
2015-โ‚น26.95 Billion60.69%
2014-โ‚น16.77 Billion98.2%
2013-โ‚น8.47 Billion
2011-โ‚น4.99 Billion27.48%
2010-โ‚น3.92 Billion-10.92%
2009-โ‚น4.4 Billion95.77%
2008-โ‚น2.25 Billion
2006-โ‚น3.6 Billion-9.13%
2005-โ‚น3.96 Billion34.74%
2004-โ‚น2.94 Billion36.79%
2003-โ‚น2.15 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚น1.488 T 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น828.36 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น476.12 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น22.96 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น4.32 Billion-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น14.52 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น195.88 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น12.82 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA